EUVIMEDOpdag EUVIMED
Übersichtsarbeit

Cathepsins: Novel opportunities for antibody therapeutics in cancer

Timothée David iD, Pénélope Desroys du Roure iD, Aude Mallavialle iD, Valérie Laurent-Matha iD, Pascal Roger iD, Séverine Guiu iD, Thierry Chardès iD, Emmanuelle Liaudet-Coopman iD

British Journal of Pharmacology · 2025-04 · 182 (8) · 1671-1682

DOI: 10.1111/bph.17437 ↗

At a glance

Übersichtsarbeit in British Journal of Pharmacology, published online on 2025-01-21. Written by Timothée David and 7 co-authors. Institution: IRCM, INSERM U1194, University of Montpellier, ICM, Montpellier, France. Major MEDLINE topics: Neoplasms, Cathepsins. Cited 9 times so far (Crossref); 71 references. Funded by: French National Research Agency, University of Montpellier, Inserm Transfert.

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

Cathepsins, the most abundant lysosomal proteases, have key functions in cell maintenance and homeostasis. They are overexpressed and hypersecreted in cancer and associated with poor prognosis. Secreted cathepsins display pro‐tumour activities in the tumour microenvironment and thus represent interesting molecular targets in oncology. Recently, several antibody‐based cancer therapies have targeted the pro‐tumour activity of the extracellular cathepsin pool, altering several cancer hallmarks, but not the intracellular cathepsin levels that are often crucial for cell homeostasis. In this mini‐review, we describe advances in antibodies against extracellular cathepsins in cancer, and their effect on the proteolytic cascade, matrix remodelling, proliferation, and modulation of the anti‐cancer immune response. We also discuss the add‐on value of combination strategies (anti‐cathepsin antibodies with chemotherapy and/or biologics) that make anti‐cathepsin antibodies a new opportunity for disease management.

Subjects

MeSH terms (MEDLINE)

NeoplasmsCathepsinsHumansAnimalsTumor Microenvironment

Author keywords

ECMantibody‐based therapybiologicscathepsinscell signallingchemotherapeutic drugsimmunomodulationproteolysistumour microenvironment

Substances

Cathepsins

Authors and institutions

  • IRCM, INSERM U1194, University of Montpellier, ICM, Montpellier, France.
  • Department of Pathology, CHU Nîmes, Nîmes, France.
  • Department of Medical Oncology, ICM, Montpellier, France.
  • Centre National de la Recherche Scientifique, CNRS, Paris, France.

ORCID profiles: Timothée David, Pénélope Desroys du Roure, Aude Mallavialle, Valérie Laurent-Matha, Pascal Roger, Séverine Guiu, Thierry Chardès, Emmanuelle Liaudet-Coopman

Funding

  • French National Research Agency
  • University of Montpellier
  • Inserm Transfert
  • Région Occitanie Pyrénées-Méditerranée
  • Ligue Nationale contre le Cancer
  • Ligue Régionale du Gard
  • Ligue Régionale de l'Herault
  • Ligue Régionale de la Charente Maritime

Cite

APA

David, T., du Roure, P. D., Mallavialle, A., Laurent-Matha, V., Roger, P., Guiu, S., Chardès, T., & Liaudet-Coopman, E. (2025). Cathepsins: Novel opportunities for antibody therapeutics in cancer. British Journal of Pharmacology, 182(8), 1671-1682. https://doi.org/10.1111/bph.17437

Vancouver

David T, du Roure PD, Mallavialle A, Laurent-Matha V, Roger P, Guiu S, et al. Cathepsins: Novel opportunities for antibody therapeutics in cancer. British Journal of Pharmacology. 2025;182(8):1671-1682. doi:10.1111/bph.17437

BibTeX
@article{David2025,
  author = {David, Timothée and du Roure, Pénélope Desroys and Mallavialle, Aude and Laurent-Matha, Valérie and Roger, Pascal and Guiu, Séverine and Chardès, Thierry and Liaudet-Coopman, Emmanuelle},
  title = {Cathepsins: Novel opportunities for antibody therapeutics in cancer},
  journal = {British Journal of Pharmacology},
  year = {2025},
  volume = {182},
  number = {8},
  pages = {1671--1682},
  doi = {10.1111/bph.17437}
}
Start for free →